Recovery peptides

BPC-157

A synthetic 15-amino-acid research peptide with extensive animal data and very limited human evidence.

Body Protection Compound 157PL 14736Pentadecapeptide BPC 157

Concise answer

What is BPC-157?

BPC-157 is a research peptide studied mostly in animals for tissue-repair pathways. It is not FDA-approved for human use, and human safety and effectiveness remain unproven.

Definition

What It Is

BPC-157 is a synthetic peptide sequence associated with research on gastric and musculoskeletal injury models. It is often promoted online for recovery, but those claims run ahead of reliable human clinical evidence.

Status

Legal and Regulatory Notes

FDA: Not FDA-approved as a drug. FDA has identified potential significant safety risks for compounded drugs containing BPC-157-related bulk substances.
Research: Most published work is preclinical. Human outcome data are not strong enough to establish safety or efficacy.
Sport: USADA describes BPC-157 as prohibited under the WADA S0 unapproved-substances category.

Research map

How BPC-157 Is Being Studied

Tendon, ligament, muscle, and bone models in animalsGastrointestinal injury modelsAngiogenesis, nitric oxide, and inflammation-related pathwaysSafety questions around immunogenicity and peptide-related impurities

People

Human Research

Human research is sparse and not adequate for confident clinical conclusions. A 2025 systematic review of musculoskeletal literature emphasized that in-human safety was not assessed by the included studies.

Models

Animal and Cell Research

Animal and cell studies are the main reason BPC-157 is discussed. Those models can generate hypotheses, but they do not prove that a compound is safe or effective in people.

Safety

Known Risks and Side Effects

Unknown long-term human safety profile
Potential immunogenicity and peptide impurity concerns identified by FDA for compounding review
Unregulated product quality and contamination risk when sold outside approved drug channels
Anti-doping risk for tested athletes

Compliance

Interpretation Guardrails

Do not interpret research-use labeling as approval for human use.
Compounded or wellness-clinic marketing claims should be checked against FDA rules and state law.
Talk to a licensed clinician before making health decisions involving injury, pain, or recovery.

Internal links

Related Battles and Profiles

Battle BPC-157 vs TB-500 Two recovery peptides with big online reputations and weak human outcome evidence. Profile TB-500 A synthetic fragment associated with thymosin beta-4 biology, with evidence often extrapolated from the parent molecule. Profile GHK-Cu A copper-binding tripeptide discussed in skin biology, cosmetic formulations, and wound-healing research. Profile Tesamorelin An FDA-approved GHRH analog product for a specific HIV-associated lipodystrophy indication. Guide Recovery Peptides A sober look at BPC-157, TB-500, and wound-healing claims without injury-cure hype. Guide Research-Only Peptides How to spot compounds where marketing has outrun human evidence and regulatory approval.

FAQ

Common Questions

Is BPC-157 FDA-approved?

No. PeptideWars classifies BPC-157 as research-only, not an FDA-approved medication.

Does BPC-157 heal injuries?

Animal studies explore tissue-repair pathways, but that is not proof that BPC-157 heals human injuries. Clinical decisions should go through a licensed clinician.

Why is BPC-157 considered high compliance risk?

It is widely marketed with treatment-like claims despite limited human data, no FDA approval, and FDA safety concerns related to compounding.

Sources

Citations and Official References

Editorial Review

Written by the PeptideWars Editorial Team. Medical reviewer placeholder: licensed clinician review should be completed before production launch. Last updated May 6, 2026.